[Clinical study on patients with advanced gastric cancer treated with oxaliplatin combining with hydroxycamptothecine].
Internal and external physiological research showed oxaliplatin could obviously suppress several kinds of tumors in combination with most anti-cancer drugs and help these drugs to kill the tumor cells. This study was designed to investigate the initial curative effects and tolerance of patients with advanced gastric cancer of treatment with combination of oxaliplatin (L-OHP) and hydroxycamptothecine (HCPT). We compared this treatment with traditional chemotherapy. In a non-randomized manner, 43 patients with advanced gastric cancer were divided into treatment group (L-OHP plus HCPT) and control group (VP-16 + CF + 5-FU) (ELF). Among these patients, 28 were male and 15 were female. The median age was 59. Karnofsky performance status(KPS) scale was more than 60. We compared the initial curative effects and tolerance between these two groups. The beneficial effects for the treatment group (24 cases) and control group (19 cases) were 58.3% (14/24) and 42.1% (8/19), respectively. Obviously, the beneficial effects to the treatment group were higher than that of the control group (P < 0.05). The side effects of both groups included bone marrow suppression, nausea, vomiting, stomatitis, neuritis, phlebitis, hair loss, and so on. But they were slight (within I and II degree). The use of L-OHP plus HCPT appears to be a very good treatment for patients with advanced gastric cancer. The patients can tolerate the side effects.